Canopy Growth (CGC) Income from Non-Controlling Interests (2019 - 2025)
Canopy Growth (CGC) reported Income from Non-Controlling Interests of $95.5 million for Q4 2025, up 965.96% sequentially from -$11.0 million in Q3 2023.
Canopy Growth (CGC) Income from Non-Controlling Interests (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 6 years of Income from Non-Controlling Interests data on file, last reported at $95.5 million in Q4 2025.
- For the quarter ending Q4 2025, Income from Non-Controlling Interests changed N/A year-over-year to $95.5 million; the trailing twelve-month figure through Dec 2025 stood at $84.5 million (changed N/A YoY), and the FY2025 full-year result was -$1.3 million, changed N/A from the prior year.
- Income from Non-Controlling Interests climbed to $95.5 million in Q4 2025, from -$11.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $95.5 million in Q4 2025 to a low of -$11.0 million in Q3 2023.
- A 4-year average of $4.7 million and a median of -$3.7 million in 2022 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 198.06% in 2022 and plunged 1015.95% in 2023, its largest moves.
- Tracing CGC's Income from Non-Controlling Interests over 4 years: stood at -$5.2 million in 2021, then surged by 38.26% to -$3.2 million in 2022, then tumbled by 242.67% to -$11.0 million in 2023, then soared by 965.96% to $95.5 million in 2025.
- Business Quant data shows CGC's Income from Non-Controlling Interests at $95.5 million in Q4 2025, -$11.0 million in Q3 2023, and -$2.8 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 95.51 Mn |
| Sep 30, 2023 | -11.03 Mn |
| Jun 30, 2023 | -2.78 Mn |
| Mar 31, 2023 | -5.57 Mn |
| Dec 31, 2022 | -3.22 Mn |
| Sep 30, 2022 | -988,335.91 |
| Jun 30, 2022 | -4.16 Mn |
| Mar 31, 2022 | 6.89 Mn |
| Dec 31, 2021 | -5.21 Mn |
| Sep 30, 2021 | -4.19 Mn |
| Jun 30, 2021 | -2.00 Mn |
| Mar 31, 2021 | -7.03 Mn |
| Dec 31, 2020 | 57.63 Mn |
| Sep 30, 2020 | -48.40 Mn |
| Jun 30, 2020 | -7.69 Mn |
| Mar 31, 2020 | -17.44 Mn |
| Dec 31, 2019 | -13.85 Mn |
| Sep 30, 2019 | -12.33 Mn |
| Jun 30, 2019 | -6.12 Mn |